Medicure Inc

Medicure Inc's capital structure shows a current ratio of 1.02, indicating a marginal ability to meet short-term obligations with current assets. The company holds CAD 3.84 million in cash and equivalents but reports negative operating cash flow of CAD -560,000 and free cash flow of CAD -4.45 million, signaling liquidity constraints. The debt-to-equity ratio of 0.07 reflects a low leverage position, with long-term debt at CAD 891,000 against total equity of CAD 12.91 million. Profitability metrics show a return on equity of -54.98% and return on assets of -28.45%, both significantly below the industry median for Biotechnology & Medical Research firms, which typically report positive ROE and ROA in the 10-20% range. Gross profit of CAD 11.75 million on CAD 28.86 million in revenue yields a 40.7% margin, but operating and net losses of CAD 6.89 million and CAD 7.10 million, respectively, indicate operational inefficiencies. The company's geographic exposure is concentrated in the United States, where it operates through Medicure Pharma Inc and Marley Drug Inc, which services all 50 states, Washington D.C., and Puerto Rico. Revenue concentration in the U.S. is not quantified in the input data, but the absence of international revenue suggests high geographic risk. Growth trajectory is mixed. The most recent actual revenue of CAD 11.61 million is below the CAD 28.86 million reported in the financial snapshot, suggesting a potential decline in the most recent period. No forward-looking revenue guidance is provided, and capital expenditure remains at zero, indicating no investment in growth infrastructure. Risk factors include low liquidity and the absence of immediate dilution threats. The company has no filing-based liquidity or dilution flags, and shares outstanding remain unchanged between basic and diluted measures at 10.44 million. However, the negative operating and free cash flows suggest potential future liquidity pressures if revenue trends do not improve. Recent events include the continued operation of Gateway Medical Pharmacy in Portland, Oregon, and the development of P5P Analogues, which may represent future product pipelines. No recent filings or transcripts are cited in the input data to indicate strategic shifts or regulatory changes.